Showing 8551-8560 of 9366 results for "".
- Practical Dermatology® Names New Interim Digital Practice Editorhttps://practicaldermatology.com/news/practical-dermatology-names-new-interim-digital-practice-editor/2461145/Practical Dermatology® magazine is proud to announce that Vishal Anil Patel, MD will serve as interim editor of our Digital Practice column. Dr. Patel is director of cutaneous oncology at GW Cancer Center, director of dermatologic surgery at GW department of der
- Boehringer Ingelheim’s Effisayil Offers Sustained Relief from GPP Flareshttps://practicaldermatology.com/news/boehringer-ingelheims-effisayil-offers-sustained-releif-from-gpp-flares/2461143/Effisayil (Spesolimab) clears skin pustules in patients with generalized pustular psoriasis (GPP) flares within the first week after treatment, and these benefits are sustained over 12 weeks, according to data presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting in Bost
- Opzelura Shows Benefit in 52-Week Phase 3 Vitiligo Studyhttps://practicaldermatology.com/news/opzelura-shows-benefit-in-52-week-phase-3-vitiligo-study/2461139/New 52-week results from the pivotal Phase 3 TRuE-V clinical trial program evaluating Incyte's topical JAK1/JAK2 inhibitor ruxolitinib cream (Opzelura™) in adolescent and adult patients with nonsegmental vitiligo show that twice daily application was
- Project IMPACT from VisualDx Marks One Yearhttps://practicaldermatology.com/news/project-impact-from-visualdx-marks-one-year-1/2461123/VisualDx marks the one-year anniversary of
- Evommune Initiates Phase 1 Study of EVO101 for Inflammatory Skin Diseaseshttps://practicaldermatology.com/news/evommune-initiates-phase-1-study-of-evo101-for-inflammatory-skin-diseases/2461117/Evommune, Inc. has enrolled the first participant in its Phase 1 study of EVO101 in healthy volunteers. EVO101 is a novel small molecule inhibitor of interleukin 1 receptor-associated kinase 4 (IRAK4) which broadly inhibits innate inflammation and is being
- Vial Welcomes David Pariser, MD to its Boardhttps://practicaldermatology.com/news/vial-welcomes-david-pariser-md-to-its-board/2461105/David Pariser, MD has joined the Vial Scientific Advisory Board. The Senior Physician at Pariser Dermatology Specialists, Dr. Pariser will share the Vial CRO team and sponsors his knowledge and insights from more than 40 years as a practicing dermatologist. The
- Dermatologists Can Support Medical, Humanitarian Efforts in Ukrainehttps://practicaldermatology.com/news/how-to-help-ukraine/2461103/Many Americans feel hopeless as they watch images of displaced Ukrainian citizens fleeing their country due to ongoing Russian attacks. EADV President Professor Alexander Stratigos and Secretary General Professor Carmen Salavastru have issued a sta
- Nancy Beesley Joins Dermavant Board of Directorshttps://practicaldermatology.com/news/nancy-beesley-joins-dermavant-board-of-directors/2461101/Nancy Beesley has been appointed to Dermavant Sciences’ Board of Directors. She joins Dermavant with more than 25 years of experience in commercializing and branding therapeutics for the treatment of various dermatological, ophthalmic, and neurologica
- Meet the Winners of the BTL Cares Scholarship Programhttps://practicaldermatology.com/news/meet-the-winners-of-the-btl-cares-scholarship-program/2461092/BTL and professional basketball player Andre Drummond have selected the five winners of their first-ever scholarship program – the BTL Scholar Draft. The program awarded each of the five students a $15,000 grant towards tuition and college fees. The
- Juvederm Volbella XC Scores FDA Nod for Undereye Hollowshttps://practicaldermatology.com/news/juvederm-volbella-xc-scores-fda-nod-for-undereye-hollows/2461071/The US Food and Drug Administration has given its nod to Allergan Aesthetics, Juvederm Volbella XC for improvement of infraorbital hollows in adults over the age of 21. Per FDA requirement for this new indication, Allergan Aesthetics is providing a product training